The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Flagged first, then by citations
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Items 401–500 of 999
Fontalis, A., Kenanidis, E. I., Kotronias, R. A., Papachristou, A., Anagnostis, P. G., Potoupnis, M. E., & Tsiridis, E. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594772 · Cited by 31
Alessandro de, S. I. R. E., Lippi, L., Aprile, V., Calafiore, D., Folli, A., D’Abrosca, F., Moalli, S., Lucchi, M., Ammendolia, A., & Invernizzi, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101626 · Cited by 31
Earnshaw, S., Graham, C. N., Ettinger, B. B., Amonkar, M. M., Lynch, N., & Middelhoven, H. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226339 · Cited by 30
Miller, P. D., Delmas, P. D., Huss, H., Patel, K., Schimmer, R. C., Adami, S., & Recker, R. R. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9403-y · Cited by 30
Self-citationEffects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
Törring, O. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15579189 · Cited by 31
Overcoming problems with adherence to osteoporosis medication
Rabenda, V., & Reginster, J. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.76 · Cited by 30
Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back
Salari, P., & Abdollahi, M. R. (2012) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3rk5j · Cited by 31
Current options for the management of postmenopausal osteoporosis
Lecart, M.-P., & Reginster, J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618123 · Cited by 30
Wezeman, F. H., Juknelis, D., Himes, R. D., & Callaci, J. J. (2007) · Bone · doi:10.1016/j.bone.2007.06.002 · Cited by 30
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
A Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.003 · Cited by 30
Vertebral fracture assessment in patients presenting with incident nonvertebral fractures
Howat, I., Carty, D., Harrison, J., Fraser, M., & McLellan, A. R. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02988.x · Cited by 29
Rietbrock, S., Olson, M. S., & van Staa, T. P. (2008) · QJM · doi:10.1093/qjmed/hcn130 · Cited by 29
Pharmacologic and nonpharmacologic management of osteoporosis
Levine, J. P. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80064-5 · Cited by 31
Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen
Pyon, E. Y. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.006 · Cited by 28
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2012) · PET Clinics · doi:10.1016/j.cpet.2012.04.001 · Cited by 28
Use of Bisphosphonates in Orthopedic Surgery
Lozano‐Calderón, S. A., Colman, M. W., Raskin, K. A., Hornicek, F. J., & Gebhardt, M. C. (2014) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2014.03.006 · Cited by 28
Miller, P. D., Recker, R. R., Harris, S. T., Silverman, S. L., Felsenberg, D., Reginster, J.-Y. L., Day, B.-M., Barr, C. E., & Masanauskaite, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2518-z · Cited by 28
Self-citationIwamoto, J., Takeda, T., & Satō, Y. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.16.2743 · Cited by 28
RetractedManagement of age-related osteoporosis and prevention of associated fractures
MacLaughlin, E. J., Sleeper, R. B., McNatty, D., & Raehl, C. L. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.3.281 · Cited by 29
Fracture liaison services: do they reduce fracture rates?
de Bruin, I. J. A., Wyers, C. E., van den Bergh, J. P., & Geusens, P. (2017) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x17706464 · Cited by 28
Eastell, R., Black, D. M., Lui, L., Chines, A. A., Marín, F., Khosla, S., de Papp, A. E., Cauley, J. A., Mitlak, B., McCulloch, C. E., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4178 · Cited by 27
An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens, G. M., Jackson, R. D., & Lewiecki, E. M. (2007) · PubMed · Cited by 28
Bauss, F., & Schimmer, R. C. (2006) · PubMed Central · Cited by 28
Self-citationOsteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
Dimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 28
Martin, K. E., Yu, J., Campbell, H. E., Abarca, J., & White, T. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.8.596 · Cited by 27
Dömötör, Z. R., Vörhendi, N., Hanák, L., Hegyi, P. J., Kiss, S., Csiki, E., Szakó, L., Párniczky, A., & Erőss, B. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573976 · Cited by 27
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 27
Monitoring osteoporosis therapies
Miller, P. D. (2007) · Current Osteoporosis Reports · doi:10.1007/bf02938621 · Cited by 27
Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis
Sultana, S., Talegaonkar, S., Ali, R., Mittal, G., Ahmad, F. J., & Bhatnagar, A. (2012) · Journal of Microencapsulation · doi:10.3109/02652048.2012.655428 · Cited by 27
Bone Densitometry: Science and Practice
Blake, G. M., & Fogelman, I. (2012) · Springer eBooks · doi:10.1007/978-3-642-02400-9_38 · Cited by 27
Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX-XXI centuries
Dedov, I. I., Mel'nichenko, G. A., Белая, Ж. Е., & Рожинская, Л. Я. (2011) · Problems of Endocrinology · doi:10.14341/probl201157135-45 · Cited by 29
Long-Term Safety of Bisphosphonate Therapy for Osteoporosis
Liberman, U. A. (2006) · Drugs & Aging · doi:10.2165/00002512-200623040-00002 · Cited by 27
Ibandronate: Pharmacology and preclinical studies
Russell, R. G. G. (2006) · Bone · doi:10.1016/j.bone.2006.01.151 · Cited by 27
Combined Pharmacologic Therapy in Postmenopausal Osteoporosis
Shen, Y., Gray, D. L., & Martinez, D. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.008 · Cited by 26
Which treatment to prevent an imminent fracture?
Iconaru, L., Baleanu, F., Charles, A., Mugisha, A., Benoit, F., Surquin, M., Karmali, R., Body, J.-J., & Bergmann, P. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101105 · Cited by 26
Fracture prevention in postmenopausal women.
Mosekilde, L., Vestergaard, P., & Langdahl, B. L. (2006) · Europe PMC (PubMed Central) · Cited by 26
Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización
Etxebarría-Foronda, Í., Caeiro-Rey, J. R., Larrainzar‐Garijo, R., Vaquero-Cervino, E., Roca-Ruiz, L., Mesa-Ramos, M., Pérez, J. M., Carpintero-Benítez, P., Cebrián, A. F., & Gil-Garay, E. (2015) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2015.05.007 · Cited by 31
What is a 'failure' of bisphosphonate therapy for osteoporosis?
CAREY, J. J. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.11.1033 · Cited by 26
Blumentals, W. A., Harris, S. T., Cole, R. E., Huang, L., & Silverman, S. L. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l555 · Cited by 26
Medical Treatment of Osteoporotic Vertebral Fractures
Langdahl, B. L., & Harsløf, T. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10392105 · Cited by 27
The effect of aminoguanidine (AG) and pyridoxamine (PM) on ageing human cortical bone
Abar, O., Dharmar, S., & Tang, S. Y. (2018) · Bone and Joint Research · doi:10.1302/2046-3758.71.bjr-2017-0135.r1 · Cited by 25
Risk factors for imminent fractures: a substudy of the FRISBEE cohort
Iconaru, L., Moreau, M., Baleanu, F., Kinnard, V., Charles, A., Mugisha, A., Surquin, M., Benoit, F., Karmali, R., Paesmans, M., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05772-8 · Cited by 26
Clinical practice guideline: The diagnosis and treatment of osteoporosis
Thomasius, F. E., Kurth, A., Baum, E., Drey, M., Maus, U. M., & Schmidmaier, R. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0222 · Cited by 25
Ramchand, S. K., Tsai, J. N., Lee, H., Sassana-Khadka, G., Jordan, M., Ryan, S. W., & Leder, B. Z. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06932-2 · Cited by 28
Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density
Adami, S., Gatti, D., Bertoldo, F., Sartori, L., Munno, O. D., Filipponi, P., Marcocci, C., Frediani, B., Palummeri, E., Fiore, C. E., et al. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9179-5 · Cited by 25
Lester, J., Dodwell, D. J., Brown, J. E., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., & Coleman, R. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.06.002 · Cited by 25
Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?
CAREY, J. J., & Palomo, L. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75a.08014 · Cited by 25
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Masud (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s8200 · Cited by 25
The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary
Yeap, S. S., Hew, F. L., Lee, J. K., Goh, E. M. L., Chee, W. S. S., Mumtaz, M., Damodaran, P., Lim, H. H., & Chan, S. P. (2013) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12037 · Cited by 27
Patients with hip fracture: What can be improved?
Siris, E. S. (2006) · Bone · doi:10.1016/j.bone.2005.11.014 · Cited by 25
Osseointegration of Cementless Implants with Different Bisphosphonate Regimens
Eberhardt, C., Stumpf, U. C., Brankamp, J., Schwarz, M., & Kurth, A. H. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000201170.57141.66 · Cited by 25
Osteoporosis in the Older Woman
Andersen, S. J. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3180dba614 · Cited by 25
Emerging pharmacologic therapies for osteoporosis
Grey, A. B. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.3.493 · Cited by 26
Epstein, S., & Zaidi, M. (2005) · Bone · doi:10.1016/j.bone.2005.05.007 · Cited by 25
Treatments for Osteoporosis — Looking beyond the HORIZON
Compston, J. E. (2007) · New England Journal of Medicine · doi:10.1056/nejme078051 · Cited by 25
Fracture prevention in postmenopausal osteoporosis: a review of treatment options
McCarus, D. C. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000197807.08697.06 · Cited by 24
Lü, K., Yin, Y., Li, C., Jin, Y., & Shan, H.-Q. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05816-z · Cited by 24
Charatcharoenwitthaya, N., Jaisamrarn, U., Songpatanasilp, T., Kuptniratsaikul, V., Unnanuntana, A., Sritara, C., Nimitphong, H., Wattanachanya, L., Chotiyarnwong, P., Amphansap, T., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.001 · Cited by 25
Pekkarinen, T., Löyttyniemi, E., & Välimäki, M. J. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2381-y · Cited by 26
The Effects of Menopause on Periodontal Tissue
Yıldırım, T. T., & Kaya, F. A. (2011) · International Dental Research · doi:10.5577/intdentres.2011.vol1.no3.2 · Cited by 24
Emerging and potential therapies for osteoporosis
Grey, A. B., & Reid, I. R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.3.265 · Cited by 22
Ibandronate in metastatic bone disease: a review of preclinical data
Bauss, F., & Body, J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200502000-00001 · Cited by 24
Osteoporosis treatment in postmenopausal women with pre-existing fracture
Cheng, M.-H., Chen, J., Fuh, J., Lee, W.-L., & Wang, P. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.04.001 · Cited by 23
Jiang, Y., Tang, H., Ma, X., Cheng, Q., Lin, H. V., Jin, X., Zhang, Z., Yu, W., He, S., Kobayashi, T., et al. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01009-9 · Cited by 24
Schini, M., Vilaça, T., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Bouxsein, M., Black, D. M., & Eastell, R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae068 · Cited by 24
Manabe, T., Mori, S., Mashiba, T., Kaji, Y., Iwata, K., Komatsubara, S., & Yamamoto, T. (2012) · Calcified Tissue International · doi:10.1007/s00223-011-9563-4 · Cited by 23
Treatment of osteoporosis in renal insufficiency
Schipper, L. G., Fleuren, H. W. H. A., van den Bergh, J. P., Meinardi, J. R., Veldman, B. A. J., & Kramers, C. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-2883-4 · Cited by 23
Ellis, A. G., Reginster, J., Luo, X., Bushmakin, A. G., Williams, R., Sutradhar, S., Mirkin, S., & Jansen, J. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.908279 · Cited by 23
Inderjeeth, C. A., Glendenning, P., Ratnagobal, S., Inderjeeth, D. C., & Ondhia, C. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s73944 · Cited by 23
Cotté, F.-E., Cortet, B., Lafuma, A., Avouac, B. P., Hasnaoui, A. E., Fardellone, P., Pouchain, D., Roux, C., & Gaudin, A.-F. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.06.004 · Cited by 25
Current and emerging therapies for osteoporosis.
Mitchner, N. A., & Harris, S. T. (2009) · PubMed · Cited by 23
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 23
Trends and determinants of prescription medication use for treatment of osteoporosis
Farley, J. F., & Blalock, S. J. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080248 · Cited by 23
Clinical use of denosumab for the treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.533651 · Cited by 23
Laster, A. J., & Lewiecki, E. M. (2007) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.04.002 · Cited by 22
Ochi, Y., Yamada, H., Mori, H., Nakanishi, Y., Nishikawa, S., Kayasuga, R., Kawada, N., Kunishige, A., Hashimoto, Y., Tanaka, M., et al. (2014) · Bone · doi:10.1016/j.bone.2014.04.023 · Cited by 23
Beard, M. K. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.643296 · Cited by 22
Mudano, A. S., Gary, L. C., de Oliveira, A., Melton, M. E., Wright, N. C., Curtis, J. R., Delzell, E., Harrington, T. M., Kilgore, M. L., Lewis, C. E., et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s44551 · Cited by 22
Bock, O., Börst, H., Beller, G., Armbrecht, G., Degner, C., Martus, P., Roth, H.-J., & Felsenberg, D. (2011) · Bone · doi:10.1016/j.bone.2011.10.027 · Cited by 22
Self-citationBisphosphonates in the treatment of metabolic bone diseases
Arantes, H. P., da Silva, A. G., & Lazaretti‐Castro, M. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200017 · Cited by 21
Understanding Patient Compliance and Persistence with Osteoporosis Therapy
Gold, D. T. (2011) · Drugs & Aging · doi:10.2165/11586880-000000000-00000 · Cited by 22
for the MOVEST Study Group, Nakamura, T., Ito, M., Hashimoto, J., Shinomiya, K., Asao, Y., Katsumata, K., Hagino, H., Inoue, T. M. N., Nakano, T., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3175-1 · Cited by 21
Agulnek, A. N., O’Leary, K. J., & Edwards, B. J.-A. (2009) · Journal of Hospital Medicine · doi:10.1002/jhm.454 · Cited by 22
The effects of zoledronate on the survival and function of human osteoblast-like cells
Huang, K., Cheng, C.-C., Chuang, P., & Yang, T. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0818-5 · Cited by 22
Epstein, S., Delmas, P. D., Emkey, R. D., Wilson, K., Hiltbrunner, V., & Schimmer, R. C. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.01.011 · Cited by 22
Self-citationQuality Indicators for the Care of Osteoporosis in Vulnerable Elders
Grossman, J., & MacLean, C. H. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01347.x · Cited by 22
Bianchi, G., & Sambrook, P. N. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802370912 · Cited by 22
New and emerging treatments for osteoporosis
Maricic, M. J. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328172dc1a · Cited by 22
Osteoporosis medication profile preference: results from the PREFER‐US study
Weiss, T. W., & McHorney, C. A. (2007) · Health Expectations · doi:10.1111/j.1369-7625.2007.00440.x · Cited by 22
Erviti, J., Alonso, Á., Gorricho, J., & López, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002084 · Cited by 21
Shi, L., Min, N., Wang, F., & Xue, Q. (2019) · BioMed Research International · doi:10.1155/2019/2594149 · Cited by 21
Polypharmacy in Osteoporosis Treatment
McConnell, M., & Shieh, A. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.05.011 · Cited by 41
Jansen, J. P., Gaugris, S., Bergman, G., & Sen, S. S. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260998 · Cited by 21
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/mjao12.11363 · Cited by 22
Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?
Ryder, K. M., Cummings, S. R., Palermo, L., Satterfield, S., Bauer, D. C., Feldstein, A. C., Schousboe, J. T., Schwartz, A. V., & Ensrud, K. E. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0622-0 · Cited by 22
Osteoporosis: how long should we treat?
Sebba, A. I. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328317ca83 · Cited by 21
Evaluating the Antifracture Efficacy of Bisphosphonates
Pazianas, M., Epstein, S., & Zaidi, M. (2009) · Reviews on Recent Clinical Trials · doi:10.2174/157488709788186030 · Cited by 21
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Lewiecki, M. E. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5645 · Cited by 21
Treatment of Postmenopausal Osteoporosis
Greenblatt, D. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.4.574.61031 · Cited by 21
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
